News

Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

3rd October 2024 Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens® New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health Investors

Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)

4th January 2024 Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC) Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous expression within tumors, and strong immunogenicity

All News

Browse our full news archives

ROME Therapeutics, Enara Bio, Nucleome Therapeutics and NYU Langone Health to Host 3rd Annual Dark Genome Symposium 8th October 2024 Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium 1st November 2023 Enara Bio highlights Dark Antigens® as a novel class of targets for developing targeted immunotherapies against solid tumors 7th November 2022 ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research 3rd November 2022 Enara Bio announces the appointment of T-cell therapy leader  Dr. Sophie Papa as Chief Medical Officer 1st February 2022 Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors 28th September 2021

Publications

Scientific posters highlighting our Dark Antigens as novel immunotherapy targets for solid tumors

Identification and validation of specific Dark Antigen™ reactive TCRs

POSTER [SITC 2023] Identification and validation of specific Dark Antigen™ reactive TCRs

Identification and validation of Dark Antigens™ in multiple solid tumors

Poster (SITC 2022) Identification and validation of Dark Antigens™ in multiple solid tumors

Identification of tumor-reactive T cells targeting melanoma Dark Antigens™

Poster (SITC 2022) Identification of tumor-reactive T cells targeting melanoma Dark Antigens™

Our early research discovering immunogenic ERV-derived antigens

POSTER (SITC 2019) Our early research discovering immunogenic ERV-derived antigens

A short selection of the growing scientific literature that inspires us to shine a light on genomic dark matter

Mobile DNA Proceedings of the inaugural Dark Genome Symposium: November 2022 Cancer Immunology Research The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides Trends in Cell Biology The dark proteome: translation from noncanonical open reading frames Genome Research LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly

Upcoming & Recent Events

Discover the events that the Enara Bio team are attending

3rd Annual Dark Genome Symposium

November 20th - 21st 2024 New York, USA

J.P. Morgan Healthcare Conference

January 8th - 11th 2024 San Francisco, California

2nd Annual Dark Genome Symposium

November 13th - 14th 2023 London, UK

BIO-Europe

November 6th - 8th 2023 Munich, Germany

38th Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 1st - 5th 2023 San Diego, US